DaVita Inc. (DVA) — 分析摘要
DaVita Inc.（DVA）的市值为12.08十亿美元，最近一年的营收同比增长了+6.5%。净利润率为5.5%。当前市盈率为14.3倍。
核心要点
- 营收同比变化+6.5%
- 净利润率5.5%
- 市盈率14.3倍
与SERVICES-MISC HEALTH & ALLIED SERVICES, NEC板块的其他公司相比，DVA的营收增长为+6.5%，市盈率为14.3倍。
DaVita Inc. (DVA)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
D/E 为 10.0x — 杠杆极高
营业利润率 (15.2%) 超过毛利率 (0.0%) — 请检查其他营业收入或数据分类问题
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
行业
SERVICES-MISC HEALTH & ALLIED SERVICES, NEC
员工人数
78,000
总部
DENVER, CO
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。